Paclitaxel (P)/carboplatin (C) versus gemcitabine (G)/vinorelbine (V) in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) - A randomized prospective phase-II-trial
G. Huebner(Westpfalz Klinikum), Hartmut Link(Medizinische Hochschule Hannover), Antje Eimermacher(Westpfalz Klinikum), C.-H. Köhne(Klinikum Oldenburg), Albrecht Kretzschmar(Roche (Switzerland)), Silke Steinbach(Krankenhaus vom Roten Kreuz), Mirjam Stahl(Humboldt-Universität zu Berlin)
Cited by 9
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k